Who are BG9418 (interferon beta-1a)'s main competitors?

Direct comparators (same drug class / molecular target / therapeutic area): Plegridy, Avonex, Betaseron, Interferon beta-1a (Rebif), Interferon beta-1a (Avonex), Rebif® (clone 484-39).

How often does this brief refresh?

Every 30 minutes from primary sources (FDA, EMA, MHRA, PMDA, ClinicalTrials.gov, USPTO). Subscribe to the RSS feed below for push alerts.

How do I get this as a recurring report?

Subscribe to /feed/ci/bg9418-interferon-beta-1a.xml in any RSS reader (Feedly, Inoreader, NewsBlur). Every regulatory action, trial readout, or patent event lands in your feed automatically.

Last reviewed 2026-06-10 · How we verify

BG9418 (interferon beta-1a) — Competitive Intelligence Brief

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

BG9418 (interferon beta-1a) (BG9418 (interferon beta-1a)) competitive landscape: 6 comparators, recent regulatory actions, upcoming PDUFA, patent timeline. Class: Interferon beta. Area: Immunology.

phase 3 Interferon beta Interferon-beta receptor (IFNAR) Immunology Small molecule Live · refreshed every 30 min

Target snapshot

BG9418 (interferon beta-1a) (BG9418 (interferon beta-1a)) — Biogen. BG9418 is interferon beta-1a, which activates interferon signaling pathways to modulate immune responses and reduce inflammation.

Comparator set (6 drugs)

Auto-detected by same drug class / molecular target / therapeutic area, ranked by phase + recency. Override with ?vs=slug1,slug2,….

Drug	Generic	Sponsor	Phase	Class	Target	Approval / PDUFA
BG9418 (interferon beta-1a) TARGET	BG9418 (interferon beta-1a)	Biogen	phase 3	Interferon beta	Interferon-beta receptor (IFNAR)
Plegridy	PEGINTERFERON BETA-1A	Biogen Idec Inc	marketed	Interferon beta [EPC]	Interferon alpha/beta receptor	2014-01-01
Avonex	INTERFERON BETA-1A	Biogen	marketed	Interferon beta [EPC]	Interferon alpha/beta receptor	1996-01-01
Betaseron	INTERFERON BETA-1B	Bayer Healthcare Pharms	marketed	Interferon beta	Interferon alpha/beta receptor	1993-01-01
Interferon beta-1a (Rebif)	Interferon beta-1a (Rebif)	Merck KGaA, Darmstadt, Germany	marketed	Interferon beta	Interferon-beta receptor (IFNAR)
Interferon beta-1a (Avonex)	Interferon beta-1a (Avonex)	Biogen	marketed	Interferon beta	Interferon-beta receptor (IFNAR)
Rebif® (clone 484-39)	Rebif® (clone 484-39)	Merck KGaA, Darmstadt, Germany	marketed	Interferon beta-1a	Type I interferon receptor (IFNAR)

Recent regulatory actions (last 90 days)

No regulatory actions in the last 90 days for this set.

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this set.

Patent timeline (forward window)

No upcoming patent expiries for this set.

Sponsor landscape (Interferon beta class)

Biogen · 2 drugs in this class
Bayer · 1 drug in this class
Bayer Healthcare Pharms · 1 drug in this class
Merck KGaA, Darmstadt, Germany · 1 drug in this class

Subscribe to ongoing alerts

Push every new event for this competitive set into your RSS reader, IFTTT/Zapier workflow, or email digest:

Cite this brief

Drug Landscape (2026). BG9418 (interferon beta-1a) — Competitive Intelligence Brief. https://druglandscape.com/ci/bg9418-interferon-beta-1a. Accessed 2026-06-10.

Build your own brief

Pick any drug + add comparators:

https://druglandscape.com/ci/{slug} — auto-detected competitors
https://druglandscape.com/ci/{slug}?vs=drug1,drug2,drug3 — explicit comparators
Brand names auto-resolve: /ci/keytruda → 301 → /ci/pembrolizumab

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing